Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. Approximately half of ADPKD patients reach end-stage renal failure by 60 years of age. ADPKD can also cause severe complications, so continuous follow up is necessary. We aimed to develop a strategy for future ADPKD practice based on the current situation of ADPKD practice at our hospital . Methods : From February 2002 to April 2016, 81 cases with ICD-10 codes related to ADPDK were registered, based on the patients’ medical records. The patients were divided into four groups according to the outcome after their introduction to our hospital . Various parameters at the first visit were compared and examined. We also investigated 19 patients who were newly introduced from May 2016 to September 2017. Results :We encountered to the fact that most ADPKD patients weren’t introduced to our department (Division of Nephrology) until end stage renal failure, which unable both proactive treatment and evaluating severe complications. We coped with this problem and succeeded to have more ADPKD patients in the early stage. Conclusion: Now that we have more ADPKD patients in the early stage, we would like to treat ADPKD by proactive practices (i.e., introduce Tolvaptan treatment for adaptation cases) at the proper timing, and at the same time, offer them continuous medical follow ups for severe complications. Eventually, we hope to develop a sufficient strategy for future ADPKD practice which we could not reach this time.
| Published in | Journal of Drug Design and Medicinal Chemistry (Volume 4, Issue 4) |
| DOI | 10.11648/j.jddmc.20180404.11 |
| Page(s) | 35-38 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2019. Published by Science Publishing Group |
ADPKD, Radiologist, Tolvaptan
| [1] | Müller RU. et al. Management of autosomal-dominant polycystic kidney disease-state-of-the-art. Clin Kidney J. 2018 Dec; 11 (Suppl 1): i2-i13. |
| [2] | Masakane I. et al. An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013). Ther Apher Dial. 2015 Dec; 19 (6):540-74. |
| [3] | Müller RU. et al. Cystic Kidney Diseases From the Adult Nephrologist's Point of View. Front Pediatr. 2018 Mar 22; 6:65. |
| [4] | Zien Zhou. et al. Is Regular Screening for Intracranial Aneurysm Necessary in Patients with Autosomal Dominant Polycystic Kidney Disease? A Systematic Review and Meta-analysis Cerebrovasc Dis 2017; 44:75–82. |
| [5] | Sung PH. et al. Risk of aortic aneurysm and dissection in patients with autosomal-dominant polycystic kidney disease: a nationwide population-based cohort study. Oncotarget. 2017 Mar 17; 8 (34):57594-57604. |
| [6] | Laia Sans-Atxer. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2018; 11; 41-51. |
| [7] | Tatsuya Suwabe. Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study. BMC Nephrol. 2013; 14; 179. |
| [8] | Cecil G Wood. CT and MR imaging for evaluation of cystic renal lesions and diseases. Radiographics. 2015 Jan-Feb; 35 (1); 125-41. |
| [9] | Brendan Smyth. Localized cystic disease of the kidney: case report and review of the literature. CEN Case Rep. 2014 Nov; 3 (2): 198–201. |
| [10] | Sharma K et al. Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS ONE 2017; 12 (5): e0178488. |
APA Style
Makoto Fukuda, Tsuyoshi Takashima, Keiichiro Matsumoto, Ken Yamaguchi, Takahiko Nakazono, et al. (2019). The Examination of the Actual State of Autosomal Dominant Polycystic Kidney Disease Treatment at Our Hospital. Journal of Drug Design and Medicinal Chemistry, 4(4), 35-38. https://doi.org/10.11648/j.jddmc.20180404.11
ACS Style
Makoto Fukuda; Tsuyoshi Takashima; Keiichiro Matsumoto; Ken Yamaguchi; Takahiko Nakazono, et al. The Examination of the Actual State of Autosomal Dominant Polycystic Kidney Disease Treatment at Our Hospital. J. Drug Des. Med. Chem. 2019, 4(4), 35-38. doi: 10.11648/j.jddmc.20180404.11
AMA Style
Makoto Fukuda, Tsuyoshi Takashima, Keiichiro Matsumoto, Ken Yamaguchi, Takahiko Nakazono, et al. The Examination of the Actual State of Autosomal Dominant Polycystic Kidney Disease Treatment at Our Hospital. J Drug Des Med Chem. 2019;4(4):35-38. doi: 10.11648/j.jddmc.20180404.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.jddmc.20180404.11,
author = {Makoto Fukuda and Tsuyoshi Takashima and Keiichiro Matsumoto and Ken Yamaguchi and Takahiko Nakazono and Hiroyuki Irie and Motoaki Miyazono and Yuji Ikeda},
title = {The Examination of the Actual State of Autosomal Dominant Polycystic Kidney Disease Treatment at Our Hospital},
journal = {Journal of Drug Design and Medicinal Chemistry},
volume = {4},
number = {4},
pages = {35-38},
doi = {10.11648/j.jddmc.20180404.11},
url = {https://doi.org/10.11648/j.jddmc.20180404.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jddmc.20180404.11},
abstract = {Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. Approximately half of ADPKD patients reach end-stage renal failure by 60 years of age. ADPKD can also cause severe complications, so continuous follow up is necessary. We aimed to develop a strategy for future ADPKD practice based on the current situation of ADPKD practice at our hospital . Methods : From February 2002 to April 2016, 81 cases with ICD-10 codes related to ADPDK were registered, based on the patients’ medical records. The patients were divided into four groups according to the outcome after their introduction to our hospital . Various parameters at the first visit were compared and examined. We also investigated 19 patients who were newly introduced from May 2016 to September 2017. Results :We encountered to the fact that most ADPKD patients weren’t introduced to our department (Division of Nephrology) until end stage renal failure, which unable both proactive treatment and evaluating severe complications. We coped with this problem and succeeded to have more ADPKD patients in the early stage. Conclusion: Now that we have more ADPKD patients in the early stage, we would like to treat ADPKD by proactive practices (i.e., introduce Tolvaptan treatment for adaptation cases) at the proper timing, and at the same time, offer them continuous medical follow ups for severe complications. Eventually, we hope to develop a sufficient strategy for future ADPKD practice which we could not reach this time.},
year = {2019}
}
TY - JOUR T1 - The Examination of the Actual State of Autosomal Dominant Polycystic Kidney Disease Treatment at Our Hospital AU - Makoto Fukuda AU - Tsuyoshi Takashima AU - Keiichiro Matsumoto AU - Ken Yamaguchi AU - Takahiko Nakazono AU - Hiroyuki Irie AU - Motoaki Miyazono AU - Yuji Ikeda Y1 - 2019/02/18 PY - 2019 N1 - https://doi.org/10.11648/j.jddmc.20180404.11 DO - 10.11648/j.jddmc.20180404.11 T2 - Journal of Drug Design and Medicinal Chemistry JF - Journal of Drug Design and Medicinal Chemistry JO - Journal of Drug Design and Medicinal Chemistry SP - 35 EP - 38 PB - Science Publishing Group SN - 2472-3576 UR - https://doi.org/10.11648/j.jddmc.20180404.11 AB - Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. Approximately half of ADPKD patients reach end-stage renal failure by 60 years of age. ADPKD can also cause severe complications, so continuous follow up is necessary. We aimed to develop a strategy for future ADPKD practice based on the current situation of ADPKD practice at our hospital . Methods : From February 2002 to April 2016, 81 cases with ICD-10 codes related to ADPDK were registered, based on the patients’ medical records. The patients were divided into four groups according to the outcome after their introduction to our hospital . Various parameters at the first visit were compared and examined. We also investigated 19 patients who were newly introduced from May 2016 to September 2017. Results :We encountered to the fact that most ADPKD patients weren’t introduced to our department (Division of Nephrology) until end stage renal failure, which unable both proactive treatment and evaluating severe complications. We coped with this problem and succeeded to have more ADPKD patients in the early stage. Conclusion: Now that we have more ADPKD patients in the early stage, we would like to treat ADPKD by proactive practices (i.e., introduce Tolvaptan treatment for adaptation cases) at the proper timing, and at the same time, offer them continuous medical follow ups for severe complications. Eventually, we hope to develop a sufficient strategy for future ADPKD practice which we could not reach this time. VL - 4 IS - 4 ER -
Information
Email: